Frontiers in Endocrinology (Aug 2023)
Increased sLRP1 and decreased atrial natriuretic peptide plasma levels in newly diagnosed T2DM patients are normalized after optimization of glycemic control
- Eduardo García,
- Eduardo García,
- Eduardo García,
- Eduardo García,
- Pedro Gil,
- Inka Miñambres,
- Aleyda Benitez-Amaro,
- Aleyda Benitez-Amaro,
- Aleyda Benitez-Amaro,
- Claudia Rodríguez,
- Lene Claudi,
- Lene Claudi,
- Lene Claudi,
- Josep Julve,
- Josep Julve,
- Josep Julve,
- Josep Julve,
- Sonia Benitez,
- Sonia Benitez,
- Sonia Benitez,
- Jose Luís Sánchez-Quesada,
- Jose Luís Sánchez-Quesada,
- Jose Luís Sánchez-Quesada,
- Jose Rives,
- Jose Rives,
- Xavier Garcia-Moll,
- David Vilades,
- David Vilades,
- David Vilades,
- Antonio Perez,
- Antonio Perez,
- Vicenta Llorente-Cortes,
- Vicenta Llorente-Cortes,
- Vicenta Llorente-Cortes,
- Vicenta Llorente-Cortes
Affiliations
- Eduardo García
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Eduardo García
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Eduardo García
- Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
- Eduardo García
- Universitat Autònoma de Barcelona, Barcelona, Spain
- Pedro Gil
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Inka Miñambres
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Aleyda Benitez-Amaro
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Aleyda Benitez-Amaro
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Aleyda Benitez-Amaro
- Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
- Claudia Rodríguez
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Lene Claudi
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Lene Claudi
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Lene Claudi
- Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
- Josep Julve
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Josep Julve
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Josep Julve
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Josep Julve
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- Sonia Benitez
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Sonia Benitez
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Sonia Benitez
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- Jose Luís Sánchez-Quesada
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Jose Luís Sánchez-Quesada
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Jose Luís Sánchez-Quesada
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- Jose Rives
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Jose Rives
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Xavier Garcia-Moll
- Cardiology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain
- David Vilades
- Cardiology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain
- David Vilades
- Cardiac Imaging Unit, Cardiology Department, Santa Creu i Sant Pau University Hospital, Barcelona, Spain
- David Vilades
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Madrid, Spain
- Antonio Perez
- Endocrinology and Nutrition Service, Hospital de la Santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Antonio Perez
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- Vicenta Llorente-Cortes
- Institut de Recerca de l’Hospital de la santa Creu i Sant Pau, Sant Quintí, Barcelona, Spain
- Vicenta Llorente-Cortes
- Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Quintí, Barcelona, Spain
- Vicenta Llorente-Cortes
- Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
- Vicenta Llorente-Cortes
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Institute of Health Carlos III, Madrid, Spain
- DOI
- https://doi.org/10.3389/fendo.2023.1236487
- Journal volume & issue
-
Vol. 14
Abstract
BackgroundLow-density lipoprotein receptor-related protein 1 (LRP1) negatively modulates circulating atrial natriuretic peptide (ANP) levels. Both molecules are involved in the regulation of cardiometabolism.ObjectivesTo evaluate soluble LRP1 (sLRP1) and ANP levels in people with newly diagnosed type 2 diabetes mellitus (T2DM) and determine the effects of metabolic optimization.MethodsThis single-center longitudinal observational study recruited patients with newly diagnosed T2DM (n = 29, HbA1c > 8.5%), and 12 healthy control, age- and sex-matched volunteers. sLRP1 and ANP levels were measured by immunoassays at T2DM onset and at one year after optimization of glycemic control (HbA1c ≤ 6.5%).ResultsT2DM had higher sLRP1 levels than the control group (p = 0.014) and lower ANP levels (p =0.002). At 12 months, 23 T2DM patients reached the target of HbA1c ≤ 6.5%. These patients significantly reduced sLRP1 and increased ANP levels. Patients who did not achieve HbA1c < 6.5% failed to normalize sLRP1 and ANP levels. There was an inverse correlation in the changes in sLRP1 and ANP (p = 0.031). The extent of sLRP1 changes over 12 months of metabolic control positively correlated with those of total cholesterol, LDL cholesterol, TG, TG/HDLc, and apolipoprotein B.ConclusionsNewly diagnosed T2DM patients have an increased sLRP1/ANP ratio, and increased sLRP1 and decreased ANP levels are normalized in the T2DM patients that reached an strict glycemic and metabolic control. sLRP1/ANP ratio could be a reliable marker of cardiometabolic function.
Keywords